Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment
An essential cytokine system for the osteoclast biology in multiple myeloma (MM) consists of the receptor of activator of NF-κB ligand (RANKL), its receptor (RANK), and the soluble decoy receptor, osteoprotegerin (OPG). Myeloma cells cause imbalance in OPG/RANKL interactions. We measured serum level...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2011/867576 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850224836490559488 |
|---|---|
| author | K. Sfiridaki C. A. Pappa G. Tsirakis P. Kanellou M. Kaparou M. Stratinaki G. Sakellaris G. Kontakis M. G. Alexandrakis |
| author_facet | K. Sfiridaki C. A. Pappa G. Tsirakis P. Kanellou M. Kaparou M. Stratinaki G. Sakellaris G. Kontakis M. G. Alexandrakis |
| author_sort | K. Sfiridaki |
| collection | DOAJ |
| description | An essential cytokine system for the osteoclast biology in multiple myeloma (MM) consists of the receptor of activator of NF-κB ligand (RANKL), its receptor (RANK), and the soluble decoy receptor, osteoprotegerin (OPG). Myeloma cells cause imbalance in OPG/RANKL interactions. We measured serum levels of OPG, soluble (s) RANKL, sRANKL/OPG ratio, markers of disease activity [LDH, CRP, interleukin-6 (IL-6), β2-microglobulin (B2M)], and angiogenic factors [hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF)], in 54 newly diagnosed MM patients and in 25 of them in plateau phase. All the above values were higher in MM patients compared to controls and decreased in plateau phase. sRANKL and RANKL/OPG were higher with advancing disease stage and skeletal grade. Significant correlations were found among RANKL and RANKL/OPG with HGF, LDH, VEGF, IL-6, and B2M. In conclusion, RANKL and OPG play significant roles in MM pathophysiology, as regulators of bone turnover and mediators of angiogenesis. |
| format | Article |
| id | doaj-art-5373bef82c2f4ff2ad00997785c50c1c |
| institution | OA Journals |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-5373bef82c2f4ff2ad00997785c50c1c2025-08-20T02:05:31ZengWileyMediators of Inflammation0962-93511466-18612011-01-01201110.1155/2011/867576867576Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to TreatmentK. Sfiridaki0C. A. Pappa1G. Tsirakis2P. Kanellou3M. Kaparou4M. Stratinaki5G. Sakellaris6G. Kontakis7M. G. Alexandrakis8Blood Bank, Venizelion General Hospital of Heraklion, 71409 Crete, GreeceBlood Bank, Venizelion General Hospital of Heraklion, 71409 Crete, GreeceDepartment of Haematology, University Hospital of Heraklion, 70013 Crete, GreeceDepartment of Haematology, University Hospital of Heraklion, 70013 Crete, GreeceDepartment of Haematology, University Hospital of Heraklion, 70013 Crete, GreeceBlood Bank, Venizelion General Hospital of Heraklion, 71409 Crete, GreeceDepartment of Surgery, University Hospital of Heraklion, 70013 Crete, GreeceDepartment of Surgery, University Hospital of Heraklion, 70013 Crete, GreeceDepartment of Haematology, University Hospital of Heraklion, 70013 Crete, GreeceAn essential cytokine system for the osteoclast biology in multiple myeloma (MM) consists of the receptor of activator of NF-κB ligand (RANKL), its receptor (RANK), and the soluble decoy receptor, osteoprotegerin (OPG). Myeloma cells cause imbalance in OPG/RANKL interactions. We measured serum levels of OPG, soluble (s) RANKL, sRANKL/OPG ratio, markers of disease activity [LDH, CRP, interleukin-6 (IL-6), β2-microglobulin (B2M)], and angiogenic factors [hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF)], in 54 newly diagnosed MM patients and in 25 of them in plateau phase. All the above values were higher in MM patients compared to controls and decreased in plateau phase. sRANKL and RANKL/OPG were higher with advancing disease stage and skeletal grade. Significant correlations were found among RANKL and RANKL/OPG with HGF, LDH, VEGF, IL-6, and B2M. In conclusion, RANKL and OPG play significant roles in MM pathophysiology, as regulators of bone turnover and mediators of angiogenesis.http://dx.doi.org/10.1155/2011/867576 |
| spellingShingle | K. Sfiridaki C. A. Pappa G. Tsirakis P. Kanellou M. Kaparou M. Stratinaki G. Sakellaris G. Kontakis M. G. Alexandrakis Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment Mediators of Inflammation |
| title | Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment |
| title_full | Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment |
| title_fullStr | Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment |
| title_full_unstemmed | Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment |
| title_short | Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment |
| title_sort | angiogenesis related cytokines rankl and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment |
| url | http://dx.doi.org/10.1155/2011/867576 |
| work_keys_str_mv | AT ksfiridaki angiogenesisrelatedcytokinesranklandosteoprotegerininmultiplemyelomapatientsinrelationtoclinicalfeaturesandresponsetotreatment AT capappa angiogenesisrelatedcytokinesranklandosteoprotegerininmultiplemyelomapatientsinrelationtoclinicalfeaturesandresponsetotreatment AT gtsirakis angiogenesisrelatedcytokinesranklandosteoprotegerininmultiplemyelomapatientsinrelationtoclinicalfeaturesandresponsetotreatment AT pkanellou angiogenesisrelatedcytokinesranklandosteoprotegerininmultiplemyelomapatientsinrelationtoclinicalfeaturesandresponsetotreatment AT mkaparou angiogenesisrelatedcytokinesranklandosteoprotegerininmultiplemyelomapatientsinrelationtoclinicalfeaturesandresponsetotreatment AT mstratinaki angiogenesisrelatedcytokinesranklandosteoprotegerininmultiplemyelomapatientsinrelationtoclinicalfeaturesandresponsetotreatment AT gsakellaris angiogenesisrelatedcytokinesranklandosteoprotegerininmultiplemyelomapatientsinrelationtoclinicalfeaturesandresponsetotreatment AT gkontakis angiogenesisrelatedcytokinesranklandosteoprotegerininmultiplemyelomapatientsinrelationtoclinicalfeaturesandresponsetotreatment AT mgalexandrakis angiogenesisrelatedcytokinesranklandosteoprotegerininmultiplemyelomapatientsinrelationtoclinicalfeaturesandresponsetotreatment |